Articles

Podcasts

Videos

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

A recent study showed anticoagulant therapy for 6 weeks compared to 3 months met noninferiority criteria, based on a combination of recurrent VTE risk and bleeding risk.


Reduced Anticoagulant Duration for VTE Noninferior in Patients Younger Than 21 Years 

The oral suspension for rivaroxaban prevents blood clots in patients aged ≥2 years with congenital heart disease following the Fontan procedure. 

FDA Approves Rivaroxaban To Treat, Prevent Blood Clots In Pediatric Patients 

Recurrent VTE shows a higher rate than expected for patients with subsegmental pulmonary embolism without proximal deep vein thrombosis managed without anticoagulation.




Subsegmental Pulmonary Embolism Linked to Increased Rate of VTE

Patients with history of VTE, peak D-dimer ≥3 μg/mL, and predischarge CRP ≥10 mg/dL were at high risk of experiencing new onset of VTE after hospital discharge. 

Postdischarge Anticoagulation Use Reduces VTE Risk After COVID-19 Hospitalization 

Incidence rates of post-Ad26.COV2.S vaccination cerebral venous sinus thrombosis was 8.65 per 100,000 person-years. 

High Incidence of CVST Observed 15 Days After COVID-19 Vaccination 

Analysis data show 3 times more risk of intensive care unit care in patients with venous thromboembolism compared to non-VTE patients (RR: 2.78). 

High Incidence of VTE Observed in ICU Hospitalizations for COVID-19

Data show postoperative initiation of factor XI inhibition was effective method for reducing the risk of VTE following total knee arthroplasty. 

Abelacimab Effective in Prevention of VTE, Including Low Bleeding Risk

The FDA Cardiovascular and Renal Drugs Advisory Committee cited concerns over an increase in thrombotic events. 

FDA Committee Recommends Against Roxadustat Approval for CKD Patients

Dabigatran etexilate was approved in both oral pellet and capsule forms for varying pediatric patient populations.

FDA Approves Oral Blood-Thinning Drug For Children with VTE

The anticoagulant did not improve clinical outcomes when compared with prophylactic anticoagulation.


Rivaroxaban Linked to Increased Bleeding Among Hospitalized COVID-19 Patients

The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.

Venous Thromboembolism